Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Update

Health Catalyst, Inc. (NASDAQ:HCAT) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,530,000 shares, a drop of 10.9% from the October 31st total of 2,840,000 shares. Based on an average trading volume of 485,300 shares, the days-to-cover ratio is presently 5.2 days.

Insider Activity

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the sale, the chief operating officer now owns 134,899 shares in the company, valued at approximately $1,036,024.32. This represents a 3.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now directly owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock worth $270,455 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

Institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA lifted its stake in shares of Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $897,000. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $6,858,000. Essex Investment Management Co. LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $2,012,000. Finally, Millrace Asset Group Inc. purchased a new position in Health Catalyst in the 3rd quarter valued at approximately $1,568,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HCAT. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Stephens upped their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Citigroup boosted their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Evercore ISI raised their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.79.

Health Catalyst Stock Down 12.0 %

Shares of HCAT traded down $1.08 during midday trading on Tuesday, reaching $7.94. The stock had a trading volume of 669,930 shares, compared to its average volume of 560,721. The company has a market cap of $483.15 million, a price-to-earnings ratio of -5.99 and a beta of 1.31. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company’s fifty day simple moving average is $8.12 and its two-hundred day simple moving average is $7.33.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the business earned ($0.22) earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. Equities research analysts expect that Health Catalyst will post -0.33 earnings per share for the current year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.